GenPath 4K score – pro
The GenPath 4Kscore combines four prostate-specific biomarkers with clinical information to provide a personalized measure of their risk for aggressive prostate cancer. The 4Kscore (Opko; BioReference Laboratories; and GenPath) is based on a prediction model of clinical variables and measured levels of four kallikrein markers: total PSA, free PSA, intact PSA and hK2. Besides predicting higher-grade cancer on biopsy, the 4Kscore predicted 15- to 20-year risk for distant metastasis or death of prostate cancer in a large population-based study.
WHile there is supportive literature, the question of whether this test can make a prospective clincial difference had not been studied or answered.
Gupta, A, Roobol, MJ, Savage, CJ, et al. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands. British Journal of Cancer, 2010;103(5):708–714. doi: 10.1038/sj.bjc.6605815.
Parekh DJ, Punnen S, Sjoberg DD, et al. A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer. Eur Urol. 2015;68:464-470.